TW252916B - - Google Patents

Info

Publication number
TW252916B
TW252916B TW081102432A TW81102432A TW252916B TW 252916 B TW252916 B TW 252916B TW 081102432 A TW081102432 A TW 081102432A TW 81102432 A TW81102432 A TW 81102432A TW 252916 B TW252916 B TW 252916B
Authority
TW
Taiwan
Prior art keywords
pyrimidyl
pyrazine
group
component selected
erhydro
Prior art date
Application number
TW081102432A
Other languages
English (en)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of TW252916B publication Critical patent/TW252916B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Materials For Medical Uses (AREA)
TW081102432A 1991-04-23 1992-03-31 TW252916B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/690,412 US5124346A (en) 1991-04-23 1991-04-23 Synergistic combinations in the treatment of anxiety

Publications (1)

Publication Number Publication Date
TW252916B true TW252916B (zh) 1995-08-01

Family

ID=24772351

Family Applications (1)

Application Number Title Priority Date Filing Date
TW081102432A TW252916B (zh) 1991-04-23 1992-03-31

Country Status (17)

Country Link
US (1) US5124346A (zh)
EP (1) EP0510837B1 (zh)
JP (1) JP2554819B2 (zh)
KR (1) KR960002181B1 (zh)
AT (1) ATE157540T1 (zh)
AU (1) AU634118B1 (zh)
CA (1) CA2066525C (zh)
DE (1) DE69221926T2 (zh)
DK (1) DK0510837T3 (zh)
HU (1) HU216632B (zh)
IE (1) IE921257A1 (zh)
IL (1) IL101626A (zh)
MX (1) MX9201858A (zh)
MY (1) MY109140A (zh)
NZ (1) NZ242429A (zh)
TW (1) TW252916B (zh)
ZA (1) ZA922898B (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5688518A (en) * 1992-02-27 1997-11-18 Alza Corporation Antidepressive therapy
US5858407A (en) * 1992-02-27 1999-01-12 Alza Corporation Method for administering tandospirone
US5478572A (en) * 1994-09-06 1995-12-26 Bristol-Myers Squibb Co. Gepirone dosage form
FR2746314B1 (fr) * 1996-03-25 1998-06-12 Pf Medicament Produit contenant du milnacipran et de l'idazoxan comme preparation pharmaceutique combinee

Also Published As

Publication number Publication date
IL101626A0 (en) 1992-12-30
US5124346A (en) 1992-06-23
EP0510837A3 (en) 1993-07-28
NZ242429A (en) 1993-08-26
DE69221926D1 (de) 1997-10-09
KR960002181B1 (ko) 1996-02-13
IE921257A1 (en) 1992-11-04
IL101626A (en) 1996-07-23
JPH05213742A (ja) 1993-08-24
ATE157540T1 (de) 1997-09-15
JP2554819B2 (ja) 1996-11-20
KR920019355A (ko) 1992-11-19
CA2066525C (en) 1995-05-30
HU216632B (hu) 1999-07-28
HUT62796A (en) 1993-06-28
DK0510837T3 (da) 1997-09-29
DE69221926T2 (de) 1998-01-02
HU9201307D0 (en) 1992-07-28
MY109140A (en) 1996-12-31
MX9201858A (es) 1992-10-01
EP0510837B1 (en) 1997-09-03
AU634118B1 (en) 1993-02-11
EP0510837A2 (en) 1992-10-28
ZA922898B (en) 1993-10-22

Similar Documents

Publication Publication Date Title
MX9702307A (es) Pirrolo (2,3-d)pirimidinas y su uso.
ZA926456B (en) 1-substituted 1H-imidazo-(4,5-c)quinolin-4-amines.
ATE244719T1 (de) N-7 heterocyclyl-pyrrolo( 2,3-d)pyrimidine und ihre verwendung
DK0938486T3 (da) Substituerede pyrrolopyrimidiner og fremgangsmåder til deres fremstilling
GEP20074227B (en) PYRROLO [2,3-d] PYRIMIDINE COMPOUNDS
EP0610317A4 (en) INHIBITORS OF DIPEPTIDYL AMINOPEPTIDASE TYPE IV.
MY123196A (en) 1,2,3-triazolo[4,5-d]pyrimidines as p2t receptor antagonists
HUT72460A (en) Synergetic antiviral nucleoside combination, pharmaceutical preparation containing thereof, method of preparation, and use
YU29202A (sh) Alkilamino supstituisani biciklični azot heterocikli kao inhibitori p38 protein kinaze
AU5501598A (en) Triazolo{4,5-(d)}pyrimidinyl derivatives and their use as medicaments
AU1485392A (en) Quinoxalines, processes for their preparation, and their use
IL118167A0 (en) Pyrazolo (1,5a) pyrimidines their preparation and use
CA2384037A1 (en) Pyrazolo[4,3-d]pyrimidines
TW252916B (zh)
EP0537937A3 (en) Substituted pyrazino 2,3-d pyrimidinones as angiotensin ii antagonists
NO874302D0 (no) Fremgangsmaate for fremstilling av 4,5-dihydro- og 4,5,6,7-tetrahydro- pyrazolo (1,5-a)pyrimidiner.
DE69201559D1 (de) Pyrimidinderivate zur erhöhung der antitumoraktivität.
AP2004002953A0 (en) 6-'2-(Phosphonomethoxy) alkoxy pyrimidine derivatives having antiviral activity.
EP0661972A4 (en) USE OF SPIPERONE OR SPIPERONE DERIVATIVES AS IMMUNODEPRESSANT AGENTS.
NZ210898A (en) 2-amino-1,2,4-triazolo(1,5-a pyrimidine derivatives and herbicidal compositions
ITMI913435A0 (it) Dispositivo per l'accoppiamento con precisione tra due parti cilindriche, in particolare per la realizzazione di utensili componibili
HU9301875D0 (en) 4-imino-quinolines, pharmaceutical preparatives containing them and methods for producing said compounds and preparatives
BG98238A (en) Substituted benzothiazole derivatives, methods for their preparation and their application as herbicides
ATE146178T1 (de) Neuroleptisch 2-substituierte perhydro-1h- pyrido(1,2-a>pyrazine
NZ219298A (en) Veterinary compositions containing 2,4-diamino-5-(8-dimethylamino-7-methyl-5-quinolylmethyl)-pyrimidine and sulphadimidine(4-amino-n-(5,6-dimethyl-2-pyrimidinyl)benzenesulphonamide)